Published: 4 March 2024
Author(s): Hong Hong, Wengen Zhu, Zhongli Xie
Issue: May 2024
Section: Letter to the Editor

Non-vitamin K oral anticoagulants (NOACs, namely dabigatran, rivaroxaban, apixaban, and edoxaban) have been widely recommended in preventing thromboembolic events among adult patients with atrial fibrillation [1], or treating acute venous thromboembolism in adults [2]. In addition, the use of NOACs in the specified population (e.g., cancer, dialysis, hypertrophic cardiomyopathy, frailty, extremes of body weight, elderly) is also examined, consistently supporting its effectiveness and safety in stroke prevention.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.